UK markets closed

CRISPR Therapeutics AG (CRSP)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
56.90+1.19 (+2.14%)
As of 03:16PM EDT. Market open.
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
Cash flows from operating activities
Net income
-217,136
-153,610
-650,175
377,661
-348,865
Depreciation & amortisation
19,619
19,837
24,172
17,953
9,184
Stock-based compensation
79,558
81,028
97,947
102,390
66,018
Change in working capital
-20,002
-193,585
19,845
26,859
33,440
Accounts receivable
0
-200,000
305
-161
-45
Other working capital
-169,054
-272,345
-532,929
457,267
-256,724
Other non-cash items
-21,461
-14,045
12,470
14,109
1,857
Net cash provided by operating activities
-159,422
-260,375
-495,741
538,972
-238,366
Cash flows from investing activities
Investments in property, plant and equipment
-9,632
-11,970
-37,188
-81,705
-18,358
Purchases of investments
-1,134,699
-1,065,911
-1,417,800
-1,509,327
-593,998
Sales/maturities of investments
1,303,349
1,452,528
1,196,333
555,602
71,186
Net cash used for investing activities
159,018
374,647
-258,655
-1,035,430
-541,170
Cash flows from financing activities
Common stock issued
313,466
32,721
970
213,267
982,289
Common stock repurchased
-
-
-
-
0
Net cash used provided by (used for) financing activities
363,194
62,664
38,592
250,945
1,016,152
Net change in cash
362,820
177,009
-715,884
-245,524
236,656
Cash at beginning of period
356,124
224,060
939,944
1,185,468
948,812
Cash at end of period
718,913
401,068
224,060
939,944
1,185,468
Free cash flow
Operating cash flow
-159,422
-260,375
-495,741
538,972
-238,366
Capital expenditure
-9,632
-11,970
-37,188
-81,705
-18,358
Free cash flow
-169,054
-272,345
-532,929
457,267
-256,724